Navigation Links
US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients During Early Morning Period
Date:11/12/2008

Data indicate Focalin XR provides rapid and significant improvements in attention, behavior and academic productivity at 30 minutes post-dose Early onset of effect may help with school preparation in the morning as well as potentially improving academic productivity for children with ADHD

EAST HANOVER, N.J., Nov. 12 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved a 30-minute onset of action for Focalin(R) XR (dexmethylphenidate HCl) extended-release capsules for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), bringing potential benefits for young patients and their families during the important morning period when they are preparing for school.

"The morning is a critical time for families," said Alice Mao, MD, Associate Professor of Psychiatry at the Baylor College of Medicine. "The early onset of Focalin XR provides symptom control which may help families and children living with ADHD get through their morning routine."

The new labeling is based on clinical study data. The most recent study, involving 86 children with ADHD between the ages of six and 12, showed that Focalin XR provided significant improvements at 30 minutes post-dose compared to placebo in measures of attention, deportment, and academic productivity.

ADHD affects approximately three to six percent of children in the United States, and its symptoms - inattention, hyperactivity and impulsivity - can significantly impact a child's ability to focus and behave in school.

A 2007 Harris survey of 1,001 caregivers of young ADHD patients revealed that caregivers were significantly more likely to report that their child's or adolescent's behavior was negatively affected in the morning compared to other periods through the day in 12 out of 16 common behaviors. These negative behaviors included lack of concentration, messiness, interrupting others, failure to complete tasks and speaking out of turn.

"The 30-minute ons
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection
2. Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million
3. Kaiser Permanente Approves $12 Million in Community Benefit Grants in Third Quarter of 2008
4. Congress Sets New Course for Lung Cancer Research; Approves $20 Million for New Defense Department Program
5. FDA Approves Nasacort AQ(R) Nasal Spray for Children Aged 2-5 years old
6. ClearWay Minnesota(SM) Board Approves New Officers
7. FDA approves first drug for Huntingtons disease
8. The California Board of Registered Nursing Approves Affiliations for Nursing Program in Glendale, California
9. Kaiser Permanente Approves $22 Million in Community Benefit Grants in Second Quarter of 2008
10. Hillenbrand, Inc. Board of Directors Approves $100M Share Repurchase Program
11. Edwards Lifesciences Board Approves New $250 Million Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Hawaii's Premier Physician Management Company, TeamPraxis, Selects Allscripts Electronic Health Record for Statewide Deployment 2Health News:Hawaii's Premier Physician Management Company, TeamPraxis, Selects Allscripts Electronic Health Record for Statewide Deployment 3Health News:Hawaii's Premier Physician Management Company, TeamPraxis, Selects Allscripts Electronic Health Record for Statewide Deployment 4Health News:R&D Quality Excellence: Proven Tactics Optimize the R&D Quality Organizations of Pharmaceutical and Biotech Industries 2Health News:Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan 2Health News:Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan 3Health News:SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results 2Health News:SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results 3Health News:SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results 4Health News:SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results 5Health News:SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results 6Health News:SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results 7Health News:SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results 8Health News:SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results 9Health News:SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results 10Health News:Bradmer announces 2007 fourth quarter and fiscal year operational and financial results 2Health News:Bradmer announces 2007 fourth quarter and fiscal year operational and financial results 3Health News:Bradmer announces 2007 fourth quarter and fiscal year operational and financial results 4Health News:Bradmer announces 2007 fourth quarter and fiscal year operational and financial results 5Health News:Bradmer announces 2007 fourth quarter and fiscal year operational and financial results 6Health News:Bradmer announces 2007 fourth quarter and fiscal year operational and financial results 7Health News:Bradmer announces 2007 fourth quarter and fiscal year operational and financial results 8Health News:Bradmer announces 2007 fourth quarter and fiscal year operational and financial results 9Health News:Bradmer announces 2007 fourth quarter and fiscal year operational and financial results 10
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4HMS Holdings Corp Hosts Second Quarter 2009 Financial Teleconference and Presentation 51790 1HMS Holdings Corp Hosts Second Quarter 2009 Financial Teleconference and Presentation 51790 2GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 1GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 2GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 3GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 4Demand for Short Term Medical Help Leads to Growth for Travel Nursing Staffing Agency 3B Prompts Move to New Location and Addition of New Online Tools 51782 1Demand for Short Term Medical Help Leads to Growth for Travel Nursing Staffing Agency 3B Prompts Move to New Location and Addition of New Online Tools 51782 2